Sponsor:
UNC Lineberger Comprehensive Cancer Center
Code:
NCT07484139
Conditions
Oral Cavity Squamous Cell Carcinoma
Head and Neck Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
XL092
Pembrolizumab
Brief summary:
Conditions
Oral Cavity Squamous Cell Carcinoma
Head and Neck Cancer
Study ID
NCT07484139
Start date
Sep 22, 2026
Status verified date
Nov, 2026
Completion date
May, 2028
Anticipated
Primary completion date
May, 2028
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
26 participants
Anticipated
Intervention Model
Single group
Primary purpose
Treatment
Arms
experimental: Locally advanced oral cavity squamous cell carcinoma
Interventions
XL092
Pembrolizumab
Primary outcome measure
Central contacts
Locations
University of North Carolina at Chapel Hill
Recruiting
Chapel Hill, North Carolina, United States, 27599
Contacts
Siddharth Sheth, MD
siddharth.sheth@unchealth.unc.eduSponsor
UNC Lineberger Comprehensive Cancer Center
Last update posted
Nov 19, 2026
Last verified
Nov, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-20. This information was provided to ClinicalTrials.gov by UNC Lineberger Comprehensive Cancer Center on 2026-11-19. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.